Search

Your search keyword '"Tochigi, Taro"' showing total 27 results
Start Over Author "Tochigi, Taro"
27 results on '"Tochigi, Taro"'

2. The development of adult T cell leukemia/lymphoma in renal transplant recipients: report of two cases with literature review

Author

Kawano, Noriaki, Kyohei, Yamada, Miyoshi, Hiroaki, Yoshida, Noriaki, Ohshima, Kouichi, Arakawa, Fumiko, Nakashima, Kazutaka, Kameda, Takuro, Kogure, Yasunori, Ito, Yuta, Yoshida, Shuro, Kuriyama, Takuro, Nakaike, Takashi, Tochigi, Taro, Takigawa, Ken, Yamashita, Kiyoshi, Toyofuku, Atsushi, Manabe, Tatsuya, Doi, Atsushi, Terasaka, Soushi, Marutsuka, Kouske, Ochiai, Hidenobu, Kikuchi, Ikuo, Mori, Yasuo, Kataoka, Keisuke, Yoshizumi, Tomoharu, Yamauchi, Junji, Yamano, Yoshihisa, and Shimoda, Kazuya

Published
2023
Full Text
View/download PDF

9. The clinical impact of the ratio of C-reactive protein to albumin (CAR) in patients with acute- and lymphoma-type adult T-cell leukemia-lymphoma (ATL)

Author

Kawano, Noriaki, primary, Shimonodan, Hidemi, additional, Nagahiro, Yuri, additional, Yoshida, Shuro, additional, Kuriyama, Takuro, additional, Takigawa, Ken, additional, Tochigi, Taro, additional, Nakaike, Takashi, additional, Makino, Shigeyoshi, additional, Yamashita, Kiyoshi, additional, Marutsuka, Kousuke, additional, Ochiai, Hidenobu, additional, Mori, Yasuo, additional, Shimoda, Kazuya, additional, Ohshima, Kouichi, additional, Mashiba, Koichi, additional, and Kikuchi, Ikuo, additional

Published
2023
Full Text
View/download PDF

12. Secondary Skin Cancer in a Case with Long-term Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Author

Kawano, Noriaki, primary, Nakamura, Shunou, additional, Mochida, Kousuke, additional, Yoshida, Shuro, additional, Kuriyama, Takuro, additional, Nakaike, Takashi, additional, Shimokawa, Tomonori, additional, Tochigi, Taro, additional, Yamashita, Kiyoshi, additional, Mashiba, Koichi, additional, Kikuchi, Ikuo, additional, Takarabe, Aina, additional, Moriguchi, Sayaka, additional, Mori, Yasuo, additional, Takenaka, Katsuto, additional, Shimoda, Kazuya, additional, Ochiai, Hidenobu, additional, and Amano, Masahiro, additional

Published
2022
Full Text
View/download PDF

15. Pharmacokinetics of anti-thymocyte globulin in a patient with severe aplastic anemia treated with allogeneic bone marrow transplantation from a matched unrelated donor

Author

Kawano, Noriaki, Matsumoto, Kana, Takami, Akiyoshi, Tochigi, Taro, Yoshida, Shuro, Kuriyama, Takuro, Nakaike, Takashi, Shimokawa, Tomonori, Yamashita, Kiyoshi, Mashiba, Koichi, Kikuchi, Ikuo, and Nakao, Shinji

Subjects
Case Report
Abstract

Anti-thymocyte globulin (ATG) is an important component of preparative regimens for allogeneic bone marrow transplantation (BMT) for aplastic anemia (AA). However, the pharmacokinetics (PK) of ATG are unclear. A 38-year-old woman with severe AA underwent BMT using a fludarabine (Flu)-based and reduced-dose cyclophosphamide (CPA)-conditioning regimen comprising rabbit ATG (2.5 mg/kg, days −7 and −6), Flu (30 mg/sqm, days −5 to −2), CPA (25 mg/kg, days −5 to −2), and total body irradiation (2 Gy, day −1), following a human leukocyte antigen-match with an unrelated donor. Notably, ATG was administered earlier than that recommended by conventional schedules. The engraftment was achieved on day 15 without reactivation of the Epstein-Barr virus and residual recipient cells. Absolute lymphocyte recovery (>0.5×10(9)/L) was achieved on day 22. The ATG concentration on day 0 and the area under the concentration-time curve (AUC) for ATG after allogeneic BMT were 21.8 μg/mL and 464 μg・day/mL, respectively. The patient remained disease-free for 6 years after BMT without acute or chronic graft-versus-host disease. Moreover, based on serum PK monitoring of ATG, including ATG concentration on day 0 and the AUC for ATG after BMT, the patient safely underwent the less-toxic, Flu-based, reduced-dose CPA regimen containing a low dose of ATG. In conclusion, we present the first report that analyzed the PK of ATG in a patient with AA treated with BMT from a matched unrelated donor. These findings might be helpful to determine ATG dosages for such patients receiving similar transplantations.

Published
2020

16. Three cases of late-onset anthracycline-related cardiomyopathy due to chemotherapies for hematological malignancy

Author

Kawano, Noriaki, primary, Kawano, Sayaka, additional, Yoshida, Shuro, additional, Kuriyama, Takuro, additional, Tochigi, Taro, additional, Nakaike, Takashi, additional, Shimokawa, Tomonori, additional, Yamashita, Kiyoshi, additional, Ochiai, Hidenobu, additional, Shimoda, Kazuya, additional, Mashiba, Koichi, additional, and Kikuchi, Ikuo, additional

Published
2020
Full Text
View/download PDF

17. Uterine relapse of Philadelphia chromosome-negative acute lymphoblastic leukemia

Author

Kawano, Noriaki, primary, Maeda, Tetsuo, additional, Kawano, Sayaka, additional, Naghiro, Yuri, additional, Takami, Akiyoshi, additional, Tochigi, Taro, additional, Nakaike, Takashi, additional, Yamashita, Kiyoshi, additional, Kodama, Takao, additional, Marutsuka, Kosuke, additional, Sugimoto, Yuka, additional, Imamura, Toshihiko, additional, Mori, Yasuo, additional, Ochiai, Hidenobu, additional, Hidaka, Tomonori, additional, Shimoda, Kazuya, additional, Mashiba, Koichi, additional, and Kikuchi, Ikuo, additional

Published
2020
Full Text
View/download PDF

18. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018)

Author

Kawano, Noriaki, primary, Yoshida, Noriaki, additional, Kawano, Sayaka, additional, Arakawa, Fumiko, additional, Miyoshi, Hiroaki, additional, Yamada, Kyohei, additional, Nakashima, Kazutaka, additional, Yoshida, Shuro, additional, Kuriyama, Takuro, additional, Tochigi, Taro, additional, Nakaike, Takashi, additional, Shimokawa, Tomonori, additional, Yamashita, Kiyoshi, additional, Marutsuka, Kousuke, additional, Mashiba, Koichi, additional, Kikuchi, Ikuo, additional, and Ohshima, Koichi, additional

Published
2019
Full Text
View/download PDF

19. Clinical Features and Treatment Outcomes of Hematopoietic Stem Cell Transplantation During 2006-2016 at a Single Institution in Miyazaki Prefecture

Author

Kawano, Noriaki, primary, Yoshida, Shuro, additional, Shimonodan, Hidemi, additional, Kuriyama, Takuro, additional, Ono, Nobuyuki, additional, Himeji, Daisuke, additional, Tochigi, Taro, additional, Nakaike, Takashi, additional, Shimokawa, Tomonori, additional, Urata, Shingo, additional, Yamashita, Kiyoshi, additional, Ito, Masaki, additional, Koketsu, Hideki, additional, Toyofuku, Atsushi, additional, Muranaka, Takahiro, additional, Marutsuka, Kousuke, additional, Mashiba, Koichi, additional, Kikuchi, Ikuo, additional, Makino, Shigeyoshi, additional, Ochiai, Hidenobu, additional, Shimoda, Kazuya, additional, Nagafuji, Koji, additional, Mori, Yasuo, additional, Miyamoto, Toshihiro, additional, and Akashi, Koichi, additional

Published
2019
Full Text
View/download PDF

20. Clinical features and treatment outcomes of opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single institution from 2006 to 2016

Author

Kawano, Noriaki, primary, Nagahiro, Yuri, additional, Yoshida, Shuro, additional, Tahara, Yoshihiro, additional, Himeji, Daisuke, additional, Kuriyama, Takuro, additional, Tochigi, Taro, additional, Nakaike, Takashi, additional, Shimokawa, Tomonori, additional, Yamashita, Kiyoshi, additional, Ochiai, Hidenobu, additional, Marutsuka, Kouske, additional, Mashiba, Koichi, additional, Shimoda, Kazuya, additional, Teshima, Takanori, additional, and Kikuchi, Ikuo, additional

Published
2019
Full Text
View/download PDF

22. Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs

Author

Tochigi, Taro, primary, Aoki, Takatoshi, additional, Kikushige, Yoshikane, additional, Kamimura, Tomohiko, additional, Ito, Yoshikiyo, additional, Shima, Takahiro, additional, Yamauchi, Takuji, additional, Mori, Yasuo, additional, Yoshimoto, Goichi, additional, Kamezaki, Kenjiro, additional, Kato, Koji, additional, Takenaka, Katsuto, additional, Iwasaki, Hiromi, additional, Akashi, Koichi, additional, and Miyamoto, Toshihiro, additional

Published
2016
Full Text
View/download PDF

24. Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.

Author

Yanagihara, Toyoshi, Ikematsu, Yuki, Kato, Koji, Yonekawa, Akiko, Ideishi, Satoko, Tochigi, Taro, Sugio, Takeshi, Miyawaki, Kohta, Tanaka, Kentaro, Harada, Eiji, Hamada, Naoki, and Nakanishi, Yoichi

Subjects
T cells, LEUKEMIA, LYMPHOMAS, HTLV, OPPORTUNISTIC infections
Abstract

The article presents case study of a 70-year-old woman cytotoxic T lymphocytes and immune deficiency in adult T cell leukemia and lymphoma. It mentions that Individuals infected with human T lymphotropic virustype 1 (HTLV-1) are susceptible to opportunistic infections with other pathogens. It presents information on precise mechanism of immune modulation in HTLV-1- positive patients.

Published
2018
Full Text
View/download PDF

25. Procalcitonin elevation in febrile recipients during pre-transplant conditioning with anti-thymocyte globulin.

Author

Shima T, Minami M, Tochigi T, Kochi Y, Jinnouchi F, Yamauchi T, Mori Y, Yoshimoto G, Mizuno S, Miyamoto T, Kato K, and Akashi K

Abstract

Infection is a major contributor to non-relapse mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Detecting infectious diseases in febrile patients during pretransplant conditioning is crucial for subsequent transplant success. Procalcitonin (PCT) is an auxiliary diagnostic marker of severe bacterial infections and has been proposed as a useful predictor of infection in patients undergoing allo-HSCT. Pre-transplant use of anti-thymocyte globulin (ATG) can cause side effects, such as fever and hypotension, which must be distinguished from infectious diseases. Although ATG administration may increase PCT levels, data on PCT levels in febrile patients after ATG administration are limited. Furthermore, no studies have compared PCT levels during allo-HSCT conditioning using ATG or non-ATG regimens. To investigate whether ATG increases PCT levels during febrile episodes in pre-transplant conditioning and whether PCT could be used to discriminate infections during this period, we analyzed 17 ATG and 59 non-ATG patients with fever and who underwent PCT level measurements during pre-transplant conditioning. Our findings revealed that ATG administration was the only significant factor that increased PCT positivity during fever ( p = 0.01). In contrast, infectious diseases did not affect PCT positivity in the ATG group ( p = 0.24). Furthermore, bloodstream infection was a significant risk factor for PCT positivity in patients who received non-ATG regimens ( p < 0.01). Incorporating PCT levels into the diagnostic workup for infectious diseases requires careful consideration, particularly for patients receiving ATG regimens., Competing Interests: The authors declare no conflict of interest. Disclosure forms provided by the authors are available on the website., (Copyright Ⓒ2024 Asia-Pacific Blood and Marrow Transplantation Group (APBMT).)

Published
2024
Full Text
View/download PDF

26. A case of successful CAR-T cell therapy for early isolated CNS recurrence of DLBCL with persistent CAR-T cells.

Author

Takigawa K, Kawano N, Mori Y, Yamauchi T, Tochigi T, Miyawaki K, Mori K, Shimo M, Nakaike T, Yamashita K, Mashiba K, Kikuchi I, Marutsuka K, Ohshima K, Kato K, and Akashi K

Abstract

Secondary central nervous system (CNS) lymphomas typically require CNS-penetrating drugs; however, the available agents are limited with temporary effects and poor outcomes. Chimeric antigen receptor T (CAR-T) cell therapy (lisocabtagene maraleucel; liso-cel) has been used to treat a few cases of isolated secondary CNS lymphoma. Herein, we report the case of a 66-year-old male diagnosed with diffuse large B-cell lymphoma (Ann Arbor grade IV; R-IPI, good risk; CNS IPI: Intermediate risk) who achieved complete remission (CR) after six courses of R-CHOP therapy. Three months later, he presented with ptosis and eye movement disorder. Systemic CT and bone marrow examination revealed no lymphoma. Although cranial-enhanced MRI showed normal findings, an increased number of B-cells (51/μL) with the original lymphoma phenotype (CD19+CD79a+CD5-CD10-CD20-Igλ+) was detected in cerebrospinal fluid (CSF), indicating an isolated CNS relapse. Seven high-dose methotrexate courses led to partial response. Subsequently, the patient received CAR-T cell therapy with tolerable adverse events - cytokine release syndrome treated with tocilizumab, no immune effector cell-associated neurotoxicity syndrome, and bone marrow failure treated with granulocyte-colony stimulating factor and eltrombopag. Sequential flow cytometry revealed a high peak of CAR-T cells and the presence of residual CAR-T cells in the peripheral blood, indicating immune surveillance of CNS lymphoma by CAR-T cells. This treatment led to a second CR. This case is the first to validate the efficacy and safety of CAR-T cell therapy for isolated secondary CNS lymphoma in clinical practice. Future accumulation of evidence on the efficacy and safety of CAR-T cell therapy is essential., Competing Interests: The authors declare no conflict of interest. Disclosure forms provided by the authors are available on the website., (Copyright Ⓒ2024 Asia-Pacific Blood and Marrow Transplantation Group (APBMT).)

Published
2024
Full Text
View/download PDF

27. Pharmacokinetics of anti-thymocyte globulin in a patient with severe aplastic anemia treated with allogeneic bone marrow transplantation from a matched unrelated donor.

Author

Kawano N, Matsumoto K, Takami A, Tochigi T, Yoshida S, Kuriyama T, Nakaike T, Shimokawa T, Yamashita K, Mashiba K, Kikuchi I, and Nakao S

Abstract

Anti-thymocyte globulin (ATG) is an important component of preparative regimens for allogeneic bone marrow transplantation (BMT) for aplastic anemia (AA). However, the pharmacokinetics (PK) of ATG are unclear. A 38-year-old woman with severe AA underwent BMT using a fludarabine (Flu)-based and reduced-dose cyclophosphamide (CPA)-conditioning regimen comprising rabbit ATG (2.5 mg/kg, days -7 and -6), Flu (30 mg/sqm, days -5 to -2), CPA (25 mg/kg, days -5 to -2), and total body irradiation (2 Gy, day -1), following a human leukocyte antigen-match with an unrelated donor. Notably, ATG was administered earlier than that recommended by conventional schedules. The engraftment was achieved on day 15 without reactivation of the Epstein-Barr virus and residual recipient cells. Absolute lymphocyte recovery (>0.5×10 9 /L) was achieved on day 22. The ATG concentration on day 0 and the area under the concentration-time curve (AUC) for ATG after allogeneic BMT were 21.8 μg/mL and 464 μg・day/mL, respectively. The patient remained disease-free for 6 years after BMT without acute or chronic graft-versus-host disease. Moreover, based on serum PK monitoring of ATG, including ATG concentration on day 0 and the AUC for ATG after BMT, the patient safely underwent the less-toxic, Flu-based, reduced-dose CPA regimen containing a low dose of ATG. In conclusion, we present the first report that analyzed the PK of ATG in a patient with AA treated with BMT from a matched unrelated donor. These findings might be helpful to determine ATG dosages for such patients receiving similar transplantations., Competing Interests: The authors declare no conflict of interest. Disclosure forms provided by the authors are available here., (Copyright Ⓒ2021 APBMT. All Rights Reserved.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results